BTTX Stock Overview
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Better Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.01 |
52 Week High | US$1.35 |
52 Week Low | US$0.005 |
Beta | 2.13 |
1 Month Change | 0.81% |
3 Month Change | -94.12% |
1 Year Change | -98.81% |
3 Year Change | -99.90% |
5 Year Change | n/a |
Change since IPO | n/a |
Recent News & Updates
Recent updates
Better Therapeutics files for FDA approval of new type of digital therapy for diabetes
Sep 22Better Therapeutics GAAP EPS of -$0.42 in-line
Aug 11Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel
May 12Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases
Nov 30Shareholder Returns
BTTX | US Healthcare Services | US Market | |
---|---|---|---|
7D | -23.1% | 1.0% | 1.6% |
1Y | -98.8% | -5.9% | 25.1% |
Return vs Industry: BTTX underperformed the US Healthcare Services industry which returned -5.9% over the past year.
Return vs Market: BTTX underperformed the US Market which returned 25.1% over the past year.
Price Volatility
BTTX volatility | |
---|---|
BTTX Average Weekly Movement | 43.3% |
Healthcare Services Industry Average Movement | 9.8% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BTTX's share price has been volatile over the past 3 months.
Volatility Over Time: BTTX's weekly volatility has increased from 25% to 43% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 54 | Frank Karbe | www.bettertx.com |
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.
Better Therapeutics, Inc. Fundamentals Summary
BTTX fundamental statistics | |
---|---|
Market cap | US$545.16k |
Earnings (TTM) | -US$31.57m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs BTTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BTTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$31.57m |
Earnings | -US$31.57m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.58 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -144.0% |
How did BTTX perform over the long term?
See historical performance and comparison